| (Values in U.S. Thousands) | Dec, 2017 | Dec, 2016 | Dec, 2015 | Dec, 2014 | Dec, 2013 |
| Sales | 20 | 20 | 30 | 70 | 400 |
| Sales Growth | unch | -33.33% | -57.14% | -82.50% | +300.00% |
| Net Income | -12,450 | -8,990 | -10,220 | -8,800 | -20,930 |
| Net Income Growth | -38.49% | +12.04% | -16.14% | +57.96% | -62.50% |
Rxi Pharmaceuticals (RXII)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
RXi Pharmaceuticals Corporation is a biotechnology company focused on discovering, developing and commercializing therapies based on its RNAi platform. The Company is developing RXI-109, which is used for the reduction of dermal scarring in planned surgeries, as well as reduces the expression of connective tissue growth factor. RXi Pharmaceuticals Corporation is based in Worcester, Massachusetts.